Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.

被引：0
|
作者：
Gutierrez, Martin
Subbiah, Vivek
Nemunaitis, John J.
Mettu, Niharika B.
Papadopoulos, Kyriakos P.
Barve, Minal A.
Feliz, Luis
Lihou, Christine Francis
Tian, Chenwei
Ji, Tao
Silverman, Ian M.
Chugh, Rashmi
Saleh, Mansoor N.
机构：
[1] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[3] Univ Toledo, Coll Med & Life Sci, 2801 W Bancroft St, Toledo, OH 43606 USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] South Texas Accelerated Res Therapeut LLC, San Antonio, TX USA
[6] Mary Crowley Canc Res Ctr, Dallas, TX USA
[7] Incyte Biosci Int Sarl, Geneva, DE, Switzerland
[8] Incyte Corp, Wilmington, DE USA
[9] Univ Michigan, Ann Arbor, MI 48109 USA
[10] Univ Alabama Birmingham, Birmingham, AL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3606
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies
    Saleh, M.
    Barve, M.
    Subbiah, V.
    Papadopoulos, K. P.
    Morgensztern, D.
    Mettu, N. B.
    Roychowdhury, S.
    Spanggaard, I.
    Veronese, M. L.
    Tian, C.
    Silverman, I. M.
    Gutierrez, M.
    ESMO OPEN, 2024, 9 (07)
  • [2] Isatuximab (Isa) plus atezolizumab (Atezo) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label multicenter study.
    Vieito Villar, Maria
    Simonelli, Matteo
    Eskens, Ferry A. L. M.
    Gil-Martin, Marta
    Yen, Chia-Jui
    Obermannova, Radka
    Chao, Yee
    Zagonel, Vittorina
    Melichar, Bohuslav
    Moreno, Victor
    Yu, Ming-Lung
    Bongiovanni, Alberto
    Calvo, Emiliano
    Rottey, Sylvie
    Machiels, Jean-Pascal
    Gonzalez-Martin, Antonio
    Paz-Ares, Luis
    Chang, Chih-Long
    Mason, Warren
    Lin, Chia-Chi
    Reardon, David
    Garralda, Elena
    Santoro, Armando
    Meng, Robin
    Abbadessa, Giovanni
    Menas, Fatima
    Lee, Helen
    Liu, Qianying
    Combeau, Cecile
    Ternes, Nils
    Massard, Christophe
    CANCER RESEARCH, 2021, 81 (13)
  • [3] FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies
    Subbiah, Vivek
    Barve, Minal
    Iannotti, Nicholas O.
    Gutierrez, Martin
    Smith, David C.
    Roychowdhury, Sameek
    Papadopoulos, Kyriakos P.
    Mettu, Niharika
    Edenfield, William J.
    Morgensztern, Daniel
    Feliz, Luis
    Lihou, Christine
    Zhen, Huiling
    Saleh, Mansoor
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [4] Safety and efficacy of leflunomide plus etanercept combination therapy in patients with rheumatoid arthritis:: Results from an open-label pilot study
    Grünke, M
    Kalden, JR
    Manger, B
    Antoni, CE
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 421 - 421
  • [5] An open-label phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced hematological malignancies
    Knurowski, Tomasz
    Searle, Emma
    Clegg, Karen
    Pegg, Neil
    West, William
    Haynes, Debbie
    Frese, Kristopher
    Somervaille, Tim C.
    CANCER RESEARCH, 2023, 83 (08)
  • [6] Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study.
    Nastoupil, Loretta J.
    Westin, Jason R.
    Fowler, Nathan Hale
    Fanale, Michelle A.
    Samaniego, Felipe
    Oki, Yasuhiro
    Obi, Chizobam
    Cao, JingJing
    Cheng, Xiaoyun
    Ma, Man Chun John
    Wang, Zhigiang
    Chu, Fuliang
    Feng, Lei
    Zhou, Shouhao
    Davis, Richard Eric
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
    Simonelli, M.
    Garralda, E.
    Eskens, F.
    Gil-Martin, M.
    Yen, C-J
    Obermannova, R.
    Chao, Y.
    Lonardi, S.
    Melichar, B.
    Moreno, V
    Yu, M-L
    Bongiovanni, A.
    Calvo, E.
    Rottey, S.
    Machiels, J-P
    Gonzalez-Martin, A.
    Paz-Ares, L.
    Chang, C-L
    Mason, W.
    Lin, C-C
    Reardon, D. A.
    Vieito, M.
    Santoro, A.
    Meng, R.
    Abbadessa, G.
    Menas, F.
    Lee, H.
    Liu, Q.
    Combeau, C.
    Ternes, N.
    Ziti-Ljajic, S.
    Massard, C.
    ESMO OPEN, 2022, 7 (05)
  • [8] Phase I/II, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101 (anti-VISTA) as monotherapy and in combination with cemiplimab in patients (pts) with advanced solid tumors
    Papadopoulos, K. P.
    Call, J. A.
    Sen, S.
    Smith, D.
    van der Horst, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S649 - S649
  • [9] Safety and Efficacy of Vibostolimab and Pembrolizumab in Patients with Relapsed or Refractory Hematologic Malignancies: A Multicohort, Open-Label, Phase 2 Study
    Yusuf, Rushdia
    Jemielita, Thomas
    Marinello, Patricia
    BLOOD, 2021, 138
  • [10] Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.
    Koshkin, Vadim S.
    Sonpavde, Guru P.
    Hwang, Clara
    Mellado, Begona
    Tomlinson, Gareth
    Shimura, Masashi
    Chisamore, Michael Jon
    Gil, Maciej
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345